Overview
- Description
Developer of therapeutic drugs intended to restore blood clotting in bleeding patients. The company's drugs use modified recombinant human coagulation factor which is capable of restoring blood clotting in the presence of direct factor anticoagulants such as rivaroxaban, apixaban, and edoxaban, enabling physicians to safely and effectively restore hemostasis in case of bleeding.
- Website
- Country
- The Netherlands
- Sector
- Health Biotechnology